Absci CEO Sean McClain Sells Shares Worth $603,751

On June 24, 2026, Sean McClain, CEO of Absci Corporation, sold 59,896 shares of the company. The shares were sold at an average price of $10.08 each, totaling approximately $603,751. This transaction was not part of a pre-planned trading scheme.

Other Institutional Activity in Absci Corporation

FMR LLC boosted its holdings in Absci by 168,995 shares, resulting in a total of 22,550,997 shares valued at about $67.7 million. ARK Investment Management LLC also increased its stake by 1,175,370 shares, bringing its total to 13,726,169 shares worth approximately $41.2 million, marking a 9.4% increase. Meanwhile, BlackRock, Inc. trimmed its position by 78,238 shares, ending with 11,255,194 shares valued at $33.8 million. Vanguard Capital Management LLC opened a new position with 5,886,640 shares valued at $17.7 million.

Absci Corporation Stock Up 21.2%

Shares of NasdaqGS:ABSI traded near $10.56 on Saturday. Absci Corporation has a market capitalization of roughly $1.73 billion. The stock's forward P/E ratio is currently negative because the company is not profitable. Absci's beta is 2.457, indicating higher volatility compared to the market. The stock has traded between $2.24 and $11.25 over the past year, with a 50-day moving average of $5.76 and a 200-day moving average of $3.84.

Insider Buying and Selling at Absci Corporation

In addition to Sean McClain's sale, other insider transactions occurred in June. Mary Szela purchased a total of 81,400 shares on June 4, 2026, while Karen McGinnis acquired 49,900 shares on the same day. These purchases did not involve any planned trading arrangements.

Analysts Set New Price Targets

On June 25, 2026, HC Wainwright & Co. maintained its buy rating on Absci with a price target of $16. Needham reiterated its buy rating with an $11 target on June 24, while BTIG maintained a buy rating with a $13 target on the same day. The consensus among analysts is a strong buy, with a mean target price of $12.4 across 10 opinions.

About Absci Corporation

Absci Corporation is a biotechnology company based in Vancouver, Washington. It focuses on developing antibody therapeutics, including treatments for inflammatory bowel disease and androgenic alopecia. The company partners with organizations like PrecisionLife and Twist Bioscience for research and development. Absci was founded in 2011 and employs about 140 people.

Bottom Line

Sean McClain's recent sale of shares in Absci Corporation is notable for investors tracking insider activity. Absci's stock has seen significant institutional interest, with several funds adjusting their positions. Analysts remain optimistic about the company's prospects, maintaining strong buy ratings. As always, remember that these filings are backward-looking and may not reflect current positions.